Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.36) by 13.89 percent. This is a 43.64 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $5.153 million which missed the analyst consensus estimate of $5.367 million by 3.98 percent. This is a 34.90 percent increase over sales of $3.820 million the same period last year.